ACETO Corporation announced that ACETO, through its wholly-owned subsidiary Rising Pharmaceuticals, signed a definitive product purchase agreement to acquire generic products and related assets of Citron Pharma LLC and Lucid Pharma LLC for a total consideration, prior to a potential earn-out payment, of approximately $412 million, or $332 million net of expected tax benefits. Vimal Kavuru, Citrons founder and CEO, joining ACETO. Vimal will serve as President of Rising Pharmaceuticals. In addition, the company expects Vimal to join the ACETO board of directors on the latter of January 1, 2017 or the closing of the transaction.